Methods for the treatment of abnormal involuntary movement disorders

  • US 10,959,996 B2
  • Filed: 07/19/2018
  • Issued: 03/30/2021
  • Est. Priority Date: 03/06/2015
  • Status: Active Grant
First Claim
Patent Images

1. A method of transitioning a human from tetrabenazine to deutetrabenazine for the treatment of chorea associated with Huntington'"'"'s disease, comprising:

  • a) discontinuing a daily amount of tetrabenazine; and

    b) administering an initial daily amount of deutetrabenazine the next day to the human,wherein the daily amount of tetrabenazine is 12.5 mg and the initial total daily amount of deutetrabenazine is 6 mg;

    orwherein the daily amount of tetrabenazine is 25 mg and the initial total daily amount of deutetrabenazine is 12 mg;

    orwherein the daily amount of tetrabenazine is 37.5 mg and the initial total daily amount of deutetrabenazine is 18 mg;

    orwherein the daily amount of tetrabenazine is 50 mg and the initial total daily amount of deutetrabenazine is 24 mg;

    orwherein the daily amount of tetrabenazine is 62.5 mg and the initial total daily amount of deutetrabenazine is 30 mg;

    orwherein the daily amount of tetrabenazine is 75 mg and the initial total daily amount of deutetrabenazine is 36 mg;

    orwherein the daily amount of tetrabenazine is 87.5 mg and the initial total daily amount of deutetrabenazine is 42 mg;

    orwherein the daily amount of tetrabenazine is 100 mg and the initial total daily amount of deutetrabenazine is 48 mg.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×